GlassScriptPhysician profile
Alexander M Jacobson
NPI 1639199169
$4,318.19
in general payments reported to CMS, 2019-2025
17 companies · $850 in 2025
The $850 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,150 · 2020: $259 · 2021: $217 · 2022: $490 · 2023: $618 · 2024: $733 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $907.59 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $867.21 | 2022-2025 | Caplyta |
| Alkermes, INC. | $519.51 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $338.65 | 2019-2025 | Invega Sustenna, Invega, Spravato |
| Abbvie INC. | $258.48 | 2022-2024 | |
| Allergan, INC. | $228.38 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $209.95 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $184.95 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $180.52 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $142.05 | 2022-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $134.74 | 2024-2025 | Cobenfy |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2019 | |
| Indivior INC. | $111.97 | 2024-2025 | Sublocade, Perseris |
| Teva Pharmaceuticals USA, INC. | $45.63 | 2019-2025 | Uzedy |
| Abbott Laboratories | $24.06 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.15 | 2020 | |
| Vanda Pharmaceuticals INC. | $19.36 | 2025 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.